DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc.

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Diamedica Therapeutics, with a price target of $14.00. Flaten...

Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyond Air (XAIR – Research Report) and Diamedica Th...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DMAC	$7.63	+5.68%	781.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DMAC	$7.63	+5.7%	781.17K
3
4
5
6

DMAC

DMAC

Get DiaMedica Therapeutics Inc. Data in Excel

Get DiaMedica Therapeutics Inc. Data in Excel